LMB64 Bacterial Extracts for Inflammatory Dermatoses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory dermatoses like atopic dermatitis and psoriasis are limited by side effects and require specific cultural conditions for bacterial extracts, making them impractical for widespread use.
Innovation Solution
Isolation and characterization of a novel bacterial strain, LMB64, from groundwater, which can be cultured on ordinary water, providing a nonpathogenic, nonfilamentous bacterium with immunomodulatory properties that modulate cytokine responses and act as a PAR2 antagonist, suitable for treating inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacterial extracts are used to treat inflammatory dermatoses, then therapeutic efficacy is improved, but specific cultural conditions are required making them impractical for widespread use
Solution Approach 1:
The patent changes the cultural parameters from complex sulfur-free mineral water to ordinary water, making the cultivation process simpler and more accessible while maintaining therapeutic efficacy. This parameter change resolves the contradiction by decoupling the therapeutic benefits from the restrictive cultural conditions.
Solution Approach 2:
The invention uses a readily available, inexpensive bacterium (Bacillus licheniformis) that can be cultured in ordinary water, replacing the need for expensive, specialized bacterial extracts requiring specific cultural conditions. This makes the therapeutic agent accessible for widespread use.
2Reliability
If standard treatments like topical corticosteroids are used, then inflammatory symptoms are controlled, but adverse effects occur particularly in children
Solution Approach 1:
The patent uses a bacterium naturally present in the environment (Bacillus licheniformis) that, rather than causing harm like pathogenic bacteria, provides therapeutic benefits by modulating the immune response. This converts the concept of harmful bacterial exposure into a beneficial therapeutic mechanism, reducing adverse effects while maintaining symptom control.
Solution Approach 2:
The bacterial extract acts as an intermediary substance that mediates between the patient's immune system and the inflammatory condition, providing a gentler alternative to direct immunosuppression by corticosteroids. This intermediary approach achieves symptom control with fewer adverse effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
LMB64's bacterial extracts induce cytokines IL-10, IL-12, and TNF-α, inhibit IL-4 and IL-6, activate Langerhans cells, and act as a TLR2, TLR4, and TLR5 agonist, offering a potential therapeutic alternative for inflammatory dermatoses with reduced side effects and simplified cultural requirements.
Implementation Method 1
A specific interaction between a motif (agonist) and a TLR triggers a cascade of complex reactions resulting in the transcription of NFκB, followed by production of pro-inflammatory and anti-inflammatory cytokines and of chemokines
Implementation Method 2
One of the causes of this inflammatory pathology is due to the activation of a G protein-coupled receptor called PAR2 (protease-activated receptor 2)... the development of PAR2 antagonists and/or protease inhibitors has a high potential to treat the pathology of pruritus
Data Source
Figure 1
Figure 2A~2B
Figure 3~4
AI summary
The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.